Navigation Links
PharmAthene Reports Year-End 2012 Financial And Operational Results
Date:3/13/2013

>

19,795,84519,613,006Property and equipment, net

483,976788,666Other long-term assets and deferred costs

113,13053,384Goodwill

2,348,4532,348,453Total assets

$   22,741,404$   22,803,509LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable

$
,697,280$
,445,700Accrued expenses and other liabilities

2,328,8772,655,330Deferred revenue

1,381,755514,312Current portion of long-term debt

749,997-Short-term debt

1,330,507-Total current liabilities

7,488,4164,615,342Other long-term liabilities

579,427449,709Long-term debt, less current portion

1,704,108-Derivative instruments

1,295,6131,886,652Total liabilities

11,067,5646,951,703Stockholders' equity:Common stock, $0.0001 par value; 100,000,000 shares authorized; 48,352,651 and 48,236,172 shares issued and outstanding at December 31, 2012 and 2011, respectively

4,8354,824Additional paid-in-capital

210,495,905208,525,917Accumulated other comprehensive (loss) income

(217,328)1,010,522Accumulated deficit

(198,609,572)(193,689,457)Total stockholders' equity

11,673,84015,851,806Total liabilities and stockholders' equity

$  22,741,404$  22,803,509 PHARMATHENE, INC.CONSOLIDATED STATEMENTS OF OPERATIONSYear Ended December 31,20122011Revenue

$ 25,175,887$  24,266,274Operating expenses:Research and development

19,509,62921,219,853General and administrative

11,628,73214,311,079Depreciation and amortization

303,916461,073Total operating expenses

31,442,27735,992,005Loss from operations

$ (6,266,390)$ (11,725,731)Other income (expense):Interest income

17,80816,660Interest expense

(342,561)(54,573)Gain on the sale of assets held for sale

-781,760Realization of cumulative translation adjustment 

1,227,656-Chan
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. PharmAthene to Present at the Noble Financial Eighth Annual Equity Conference on Tuesday, January 17, 2012
2. PharmAthene to Present at the 24th Annual ROTH Conference on Monday, March 12, 2012
3. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
4. PharmAthene Presents Update on SparVax™ rPA Anthrax Vaccine Program at the 2012 World Vaccine Congress
5. PharmAthene Reports First Quarter 2012 Financial Results
6. PharmAthene Reports Third Quarter 2012 Financial Results
7. PharmAthene To Present At The Noble Financial 9th Annual Equity Conference On Tuesday, January 22, 2013
8. PharmAthene To Host Year-End 2012 Conference Call And Webcast On Wednesday, March 13, 2013
9. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
10. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
11. Interleukin Genetics Reports Third Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... 26, 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... testing solutions for the detection of foodborne pathogens, today ... the Sidoti & Company Emerging Growth Conference on September ... at the New York Marriott Marquis. ... through the investor relations section of Roka Bioscience,s website ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 2015 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic ... announced that the Company has been informed that Magnum ... owned by Mr. Yuen Kam, chairman of the board ... shares (the "Shares") of  Excellent China Healthcare Investment Limited ...
(Date:8/26/2015)... , ... August 26, 2015 , ... PRC Clinical, ... develop new business relationships with local sponsors in southern California. The Clinical Trial Management ... drug development processes and regulatory pathways., , Stem Cell ...
Breaking Biology Technology:Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 2China Cord Blood Corporation Receives Notice of Transactions Regarding its 7% Senior Convertible Notes Due 2017 3PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 2PRC Clinical To Attend Major Industry Conferences And Meet Sponsor Companies In The San Diego Biotech Hub 3
... Multiple Ultrasound Solution Provider Doubles Sales Over Same Period Last ... ... WAUKESHA, Wis., Aug. 27 MedPro Imaging, a premier,provider of ... representing a doubling of sales,over the same period last year. Recent ...
... Following the successful acquisition of,Drug Development Solutions (,DDS,) ... today that it has fully,integrated its two early ... Early Phase., Chiltern Early Phase is providing ... via its two well established units in Slough,(just ...
... Inc. (Nasdaq: AMLN ) and Eli Lilly and ... provided context and additional information,regarding the August 18, 2008 ... alert for BYETTA(R) (exenatide) injection referencing,pancreatitis. The companies were ... well as others, and previously reported these cases to ...
Cached Biology Technology:MedPro Installs 1000th Ultrasound System Worldwide 2Chiltern Early Phase: Fully Integrated and Business Ready 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 2Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 3Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 4Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 5Amylin Pharmaceuticals and Eli Lilly Provide Context for FDA Alert for BYETTA 6
(Date:7/31/2015)... China , 31 de julio de 2015 /PRNewswire/ ... Genómica (ICG-10,  www.icg-10.org ) del 22 al 25 de ... . La conferencia celebra su décimo aniversario ... ha convertido en una de las reuniones anuales más ... y es una de las conferencias científicas más dinámicas, ...
(Date:7/31/2015)... SHENZHEN, China , 31 de julio de 2015 /PRNewswire/ ... www.icg-10.org ) se celebrará por medio de BGI del 22 ... China . Este año, la conferencia ... 2006, ICG se ha convertido en una de las reuniones ... de ser una de las reuniones más dinámicas, entusiastas y ...
(Date:7/31/2015)... July 31, 2015 The 10 th International ... by BGI from October 22-25, 2015, in Shenzhen ... conference is celebrating its 10 th anniversary this year. Since ... world,s most influential annual meetings in the ,omics, fields, and ... gatherings. ICG-10 focuses on recent breakthroughs and ...
Breaking Biology News(10 mins):La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 2La 10ª Conferencia Internacional sobre Genómica (ICG-10) comienza en octubre 3La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2
... cancer as a major cause of death among children ... adequately addressed by national or international health organizations and ... Hospital. This growing rate of pediatric cancer is occurring ... is being reduced through the efforts of the World ...
... prices at the gas pump could come in the ... biomass, according to a joint feasibility study for the ... Oak Ridge National Laboratory report outlines a national strategy ... organic matter that is available on a renewable or ...
... everything was big has helped Queensland researchers to unearth ... responsible for wiping out Australian giant marsupials or megafauna ... specimens' such as giant kangaroos and wombats, the researchers ... performed the first systematic analysis of a site in ...
Cached Biology News:Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 2Emergence of cancer as major cause of childhood death in developing countries is not being adequately addressed 3Human Cells Filmed Instantly Messaging for First Time 2Small species back-up giant marsupial climate change extinction claim 2Small species back-up giant marsupial climate change extinction claim 3
IHC Polymer Detection Kit (Rabbit DAB)150 slides...
...
Mus musculus junctophilin 2 (Jph2) Antigen: Recombinant Protein...
Carp Vitellogenin ELISA System, 96 wells. ELISARange: 5.0-225 ng/ml.Sensitivity: 5.0 ng/ml.Sample volume: 100 ul.Suitable for use with Carp plasma samples.3-h protocol.Store at 2-8 C. Category: Drug ...
Biology Products: